Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > Targeted O-glycoproteomics explored increased sialylation and identified MUC16 as a poor prognosis biomarker in advanced-stage bladder tumours
Publication

Publications

Targeted O-glycoproteomics explored increased sialylation and identified MUC16 as a poor prognosis biomarker in advanced-stage bladder tumours

Title
Targeted O-glycoproteomics explored increased sialylation and identified MUC16 as a poor prognosis biomarker in advanced-stage bladder tumours
Type
Article in International Scientific Journal
Year
2017
Authors
Cotton, S
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Azevedo, R
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Gaiteiro, C
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Ferreira, D
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Lima, L
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Peixoto, A
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Fernandes, E
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Neves, M
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Neves, D
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Amaro, T
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Cruz, R
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Tavares, A
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Silva, AMN
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. View Authenticus page Without ORCID
Santos, LL
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Ferreira, JA
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Journal
Title: Molecular OncologyImported from Authenticus Search for Journal Publications
Vol. 11
Pages: 895-912
ISSN: 1574-7891
Publisher: Wiley-Blackwell
Other information
Authenticus ID: P-00N-9X4
Abstract (EN): Bladder carcinogenesis and tumour progression is accompanied by profound alterations in protein glycosylation on the cell surface, which may be explored for improving disease management. In a search for prognosis biomarkers and novel therapeutic targets we have screened, using immunohistochemistry, a series of bladder tumours with differing clinicopathology for short-chain O-glycans commonly found in glycoproteins of human solid tumours. These included the Tn and T antigens and their sialylated counterparts sialyl-Tn(STn) and sialyl-T(ST), which are generally associated with poor prognosis. We have also explored the nature of T antigen sialylation, namely the sialyl-3-T(S3T) and sialyl-6-T(S6T) sialoforms, based on combinations of enzymatic treatments. We observed a predominance of sialoglycans over neutral glycoforms (Tn and T antigens) in bladder tumours. In particular, the STn antigen was associated with high-grade disease and muscle invasion, in accordance with our previous observations. The S3T and S6T antigens were detected for the first time in bladder tumours, but not in healthy urothelia, highlighting their cancer-specific nature. These glycans were also overexpressed in advanced lesions, especially in cases showing muscle invasion. Glycoproteomic analyses of advanced bladder tumours based on enzymatic treatments, Vicia villosa lectin-affinity chromatography enrichment and nanoLC-ESI-MS/MS analysis resulted in the identification of several key cancer-associated glycoproteins (MUC16, CD44, integrins) carrying altered glycosylation. Of particular interest were MUC16 STn (+)-glycoforms, characteristic of ovarian cancers, which were found in a subset of advanced-stage bladder tumours facing the worst prognosis. In summary, significant alterations in the O-glycome and O-glycoproteome of bladder tumours hold promise for the development of novel noninvasive diagnostic tools and targeted therapeutics. Furthermore, abnormal MUC16 glycoforms hold potential as surrogate biomarkers of poor prognosis and unique molecular signatures for designing highly specific targeted therapeutics.
Language: English
Type (Professor's evaluation): Scientific
No. of pages: 18
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same journal

The Porto European Cancer Research Summit 2021 (2021)
Another Publication in an International Scientific Journal
Ringborg, U; Berns, A; Celis, JE; Heitor, M; Tabernero, J; Schuz, J; Baumann, M; Henrique, R; Aapro, M; Basu, P; Beets Tan, R; Besse, B; Cardoso, F; Carneiro F; van den Eede, G; Eggermont, A; Frohling, S; Galbraith, S; Garralda, E; Hanahan, D...(mais 29 authors)
Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer (2018)
Article in International Scientific Journal
Bruun, J; Sveen, A; Barros, R; Eide, PW; Eilertsen, I; Kolberg, M; Pellinen, T; David L; Svindland, A; Kallioniemi, O; Guren, MG; Nesbakken, A; Raquel Almeida; Lothe, RA
Pharmacological NF-?B inhibition decreases cisplatin chemoresistance in muscle-invasive bladder cancer and reduces cisplatin-induced toxicities. (2023)
Article in International Scientific Journal
da Costa, RMG; Levesque, C; Bianchi-Frias, D; Chatterjee, P; Lam, HM; Santos, C; Coleman, IM; Ferreirinha, P; Manuel Vilanova; da Cunha, NP; Carvalho, H; Moreira-Pais, A; Faustino-Rocha, A; Neto, T; da Costa, JB; Wright, JL; Ferreira, R; Oliveira, PA; Joaquim Mendes; Margarida Bastos...(mais 5 authors)
Overexpression of tumour-associated carbohydrate antigen sialyl-Tn in advanced bladder tumours (2013)
Article in International Scientific Journal
Ferreira, JA; Videira, PA; Lima, L; Pereira, S; Silva, M; Carrascal, M; Seuerino, PF; Fernandes, E; Almeida, A; Costa, C; Vitorino, R; Amaro, T; Oliveira, MJ; Celso Reis; Dall'Olio, F; Amado, F; Lucio Lara Santos
Histological and mutational profile of diffuse gastric cancer: current knowledge and future challenges (2021)
Article in International Scientific Journal
Garcia Pelaez, J; Barbosa Matos, R; Gullo, I; Carneiro F; Oliveira, C

See all (8)

Recommend this page Top
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-07-18 at 21:19:52 | Privacy Policy | Personal Data Protection Policy | Whistleblowing